The use of immunoconjugates in cancer therapy

M. A. Ghetie, V. Ghetie, E. S. Vitetta

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Those immunoconjugates that have entered clinical trials (i.e., immunotoxins, radiolabelled and bispecific antibodies) have shown promising antitumour activity in haematopoietic tumours (lymphomas/leukaemias). To eliminate large solid tumours, immunoconjugates will require changes in both the antibody and effector moieties since these tumours are poorly vascularised and rarely express tumour-specific antigens. This review describes improvements which may have a major impact on the next generation of immunoconjugates.

Original languageEnglish (US)
Pages (from-to)309-321
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume5
Issue number3
StatePublished - Jan 1 1996

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this